Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2025)

Regeneron Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $986.8 million for Q4 2025.

• On a quarterly basis, Operating Leases rose 3.39% year-over-year to $986.8 million in Q4 2025; TTM through Dec 2025 was $986.8 million, a 3.39% increase from a year earlier, with the FY2025 full-year figure at $986.8 million, up 3.39% from the prior year.
• Operating Leases advanced to $986.8 million in Q4 2025 per REGN's latest filing, from $954.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $986.8 million in Q4 2025 and bottomed at $788.2 million in Q4 2022.
• The 4-year median for Operating Leases is $881.0 million (2023), against an average of $884.3 million.
• Across the five-year window, Operating Leases rose 2.47% in 2023 and climbed 18.16% in 2024, its largest moves.
• Year by year, Operating Leases stood at $788.2 million in 2022, then increased by 2.47% to $807.7 million in 2023, then increased by 18.16% to $954.4 million in 2024, then climbed by 3.39% to $986.8 million in 2025.
• Per Business Quant, the three latest REGN Operating Leases figures stand at $986.8 million (Q4 2025), $954.4 million (Q4 2024), and $807.7 million (Q4 2023).